Patents by Inventor Christian Ringemann

Christian Ringemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10332632
    Abstract: Methods and systems are disclosed for determining a basal rate adjustment of insulin in a continuous glucose monitoring system of a person with diabetes. A method may include receiving, by at least one computing device, a signal representative of at least one glucose measurement and detecting, by the at least one computing device, a glucose state of the person based on the signal, the detected glucose state including a glucose level of the person and a rate of change of the glucose level. The method may also include calculating, by the at least one computing device, an adjustment to a basal rate of a therapy delivery device based on a control-to-range algorithm and at least one failsafe constraint to account for changes in the insulin sensitivity of the person with diabetes or inaccurate glucose measurement.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: June 25, 2019
    Assignee: Roche Diabetes Care, Inc.
    Inventors: David L. Duke, Christian Ringemann, Chinmay Uday Manohar
  • Patent number: 10297350
    Abstract: Methods and systems are disclosed for determining a basal rate adjustment of insulin based on risk associated with a glucose state of a person with diabetes. A method may include detecting a glucose state of the person based on a received glucose measurement signal and determining a current risk metric associated with the detected glucose state. The method may include determining a current risk metric associated with the detected glucose state based on a weighted average of cumulative hazard values of return paths generated from a glucose state distribution around a detected glucose state. The method may include calculating an adjustment to a basal rate of a therapy delivery device based on the current risk metric associated with the detected glucose state and a reference risk metric associated with a reference glucose level.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: May 21, 2019
    Assignee: Roche Diabetes Care, Inc.
    Inventors: David L. Duke, Christian Ringemann, Chinmay Uday Manohar, Alan Greenburg
  • Publication number: 20190133506
    Abstract: A method for providing a signal quality degree associated with an analyte value measured in a continuous monitoring system is disclosed. The method includes the steps of: receiving a measured analyte value from a biosensor; determining at least two impact parameters, wherein each of the impact parameters is influenced by an operational status of the continuous monitoring system and wherein each of the impact parameters is capable of exerting an influence on the signal quality of the biosensor and wherein the influence of each of the impact parameters on the signal quality of the biosensor is expressed by a weight assigned to each of the impact parameters; and determining the signal quality degree associated with the measured analyte value as a function of the weights and the corresponding impact parameters; and providing the signal quality degree associated with the analyte value. Further methods are also disclosed.
    Type: Application
    Filed: December 21, 2018
    Publication date: May 9, 2019
    Inventor: Christian Ringemann
  • Publication number: 20190079044
    Abstract: A method for detecting an interferent contribution in a biosensor is disclosed. Herein, the biosensor has a first electrode (112), a second electrode, and a third electrode (114), wherein the first electrode (112) and the second electrode are covered by a membrane, wherein the first electrode (112) further includes an enzyme or wherein the first electrode (112) is covered by an enzyme layer. Further, the first electrode (112), the second electrode, and the third electrode (114) are connected via a potentiostat, wherein, in a normal operational mode, via the potentiostat an electrical potential difference is applied between the first electrode (112) and the second electrode in a manner that the first electrode (112) allows for oxidative processes and the third electrode (114) allows for reductive processes.
    Type: Application
    Filed: March 14, 2017
    Publication date: March 14, 2019
    Inventors: Christian Ringemann, Herbert Wieder
  • Publication number: 20190069822
    Abstract: A sensor device for detecting at least one analyte in a body fluid of a user. The sensor device includes an evaluation device for evaluating a data stream of time-dependent concentrations c of the analyte. The evaluation device includes a comparator device for comparing a current value c(t) of the concentration c with a first threshold value L and a second threshold value H, wherein H>L. The evaluation device defines a tolerance time interval. Further, the evaluation device, by using the comparator device, is configured to detect if the concentration c rises and exceeds the first threshold value L during the tolerance time interval and to prepare a warning signal W accordingly. The evaluation device is configured to suppress an output of the warning signal W at least until the tolerance time interval expires, under the precondition that c(t)<H during the tolerance time interval.
    Type: Application
    Filed: October 31, 2018
    Publication date: March 7, 2019
    Inventors: Christian Ringemann, Bernd Steiger
  • Publication number: 20180328854
    Abstract: The invention concerns a method and an apparatus for determining the concentration of an analyte in a body fluid, where the following measures are proposed: providing a layered test element (12) including an enzyme-based chemistry layer which is responsive to the analyte by a color change, applying a sample of the body fluid onto the test element (12), detecting by means of a photometric reflectance measuring device (16) a reflectance value of the test element (12), correcting the measured reflectance value by a predetermined offset value attributed to the test element (12), determining a concentration value of the analyte using the offset-corrected reflectance value.
    Type: Application
    Filed: November 21, 2016
    Publication date: November 15, 2018
    Inventors: Alexander Ibach, Christian Ringemann, Peter Stephan
  • Publication number: 20170348484
    Abstract: Methods and systems are disclosed for determining a basal rate adjustment of insulin based on risk associated with a glucose state of a person with diabetes. A method may include detecting a glucose state of the person based on a received glucose measurement signal and determining a current risk metric associated with the detected glucose state. The method may include determining a current risk metric associated with the detected glucose state based on a weighted average of cumulative hazard values of return paths generated from a glucose state distribution around a detected glucose state. The method may include calculating an adjustment to a basal rate of a therapy delivery device based on the current risk metric associated with the detected glucose state and a reference risk metric associated with a reference glucose level.
    Type: Application
    Filed: June 1, 2016
    Publication date: December 7, 2017
    Inventors: David L. Duke, Christian Ringemann, Chinmay Uday Manohar, Alan Greenburg
  • Publication number: 20170348483
    Abstract: A method and system of determining a basal rate adjustment of insulin in a continuous glucose monitoring system of a person with diabetes is provided. The method includes receiving, by at least one computing device, a signal representative of at least one glucose measurement; detecting, by the at least one computing device, a glucose state of the person based on the signal, the detected glucose state including a glucose level of the person and a rate of change of the glucose level; determining, by the at least one computing device, a current risk metric, the current risk metric indicating a risk of at least one of a hypoglycemic condition and a hyperglycemic condition of the person; and calculating, by the at least one computing device, an adjustment to a basal rate of a therapy delivery device based on the current risk metric and a control-to-range algorithm comprising at least one aggressiveness parameter.
    Type: Application
    Filed: June 1, 2016
    Publication date: December 7, 2017
    Inventors: David L. Duke, Alan Greenburg, Christian Ringemann, Chinmay Uday Manohar
  • Publication number: 20170348482
    Abstract: Methods and systems are disclosed for determining a basal rate adjustment of insulin in a continuous glucose monitoring system of a person with diabetes. A method may include receiving, by at least one computing device, a signal representative of at least one glucose measurement and detecting, by the at least one computing device, a glucose state of the person based on the signal, the detected glucose state including a glucose level of the person and a rate of change of the glucose level. The method may also include calculating, by the at least one computing device, an adjustment to a basal rate of a therapy delivery device based on a control-to-range algorithm and at least one failsafe constraint to account for changes in the insulin sensitivity of the person with diabetes or inaccurate glucose measurement.
    Type: Application
    Filed: June 1, 2016
    Publication date: December 7, 2017
    Inventors: David L. Duke, Christian Ringemann, Chinmay Uday Manohar
  • Publication number: 20170319112
    Abstract: The present disclosure refers to a method for determining a blood glucose level for a patient, the method comprising detecting a present sensor signal in a present continuous interstitial blood glucose measurement for a patient; providing measurement data representing the present sensor signal; providing sensor signal correction data representing a patient-specific signal correction, the sensor signal correction data being determined from a former interstitial blood glucose measurement for the patient and comprising at least one of time delay data representing a patient-specific time delay ?t between a blood glucose value measured in a continuous interstitial blood glucose measurement and a blood glucose reference value measured in a capillary blood glucose measurement, and sensor sensitivity data representing, for the patient, a patient-specific sensor sensitivity for the sensor, determining corrected measurement data representing a corrected present sensor signal by applying the sensor signal correction dat
    Type: Application
    Filed: June 20, 2017
    Publication date: November 9, 2017
    Applicant: Roche Diabetes Care, Inc.
    Inventors: Guenther Schmelzeisen-Redeker, Nikolaus Schmitt, Christian Ringemann
  • Patent number: 9611504
    Abstract: An analytical apparatus is disclosed for detecting at least one analyte in a sample, where in an analyte measurement at least an electrical or optical property changeable by presence of the analyte at least one test chemical of a test element is recorded, and where the analytical apparatus also can perform at least one quality measurement on the at least one test chemical such as an intrinsic luminescence, which is recorded and from the intrinsic luminescence a conclusion is drawn on a quality of the test chemical and thus the test element. Methods also are disclosed for detecting at least one analyte in a sample that include a quality measurement of the at least one test chemical of the test strip.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: April 4, 2017
    Assignee: Roche Diabetes Care, Inc.
    Inventors: Wolfgang Petrich, Carina Horn, Nelli Steinke, Christian Ringemann, Alexa Freifrau von Ketteler
  • Publication number: 20170073728
    Abstract: Analytical apparatuses are disclosed for detecting at least one analyte in a sample, where in an analyte measurement at least an electrical or optical property changeable by presence of the analyte at least one test chemical of a test element is recorded, and where the analytical apparatus also can perform at least one quality measurement on the at least one test chemical such as an intrinsic luminescence, which is recorded and from the intrinsic luminescence a conclusion is drawn on a quality of the test chemical and thus the test element. Methods also are disclosed for detecting at least one analyte in a sample that include a quality measurement of the at least one test chemical of the test strip.
    Type: Application
    Filed: November 22, 2016
    Publication date: March 16, 2017
    Inventors: Wolfgang Petrich, Carina Horn, Nelli Steinke, Christian Ringemann, Alexa Freifrau von Ketteler
  • Publication number: 20160011120
    Abstract: Methods are provided for deriving/determining an analyte concentration that include recording measurement values during a time development indicating a progress of a detection reaction of at least one test substance and a body fluid sample and providing at least one measurement curve F(t) containing the measurement values, where the detection reaction is known to be influenced by the analyte concentration and at least one disturbance variable Y. The methods also include deriving an end value of the measurement curve to form a first variable x1, and deriving at least one fit parameter by taking into account an exponential characteristic of the measurement curve, and where the fit parameter forms at least one second variable x2. The methods further include deriving/determining the analyte concentration by using at least one multivariate evaluation algorithm adapted to combine x1 and x2. Also provided are computer programs and devices that incorporate the same.
    Type: Application
    Filed: June 19, 2015
    Publication date: January 14, 2016
    Applicant: Roche Diabetes Care, Inc.
    Inventors: Christian Ringemann, Markus Plum, Wolfgang Petrich, Timo Ottenstein
  • Publication number: 20160011178
    Abstract: Methods for detecting an analyte in a body fluid are described as well as devices and systems adapted for performing such methods. In embodiments of the method, a sample of body fluid is applied to a test element having at least one test field including at least one test material that is adapted to change at least one measurable property in the presence of the analyte. The test element further includes a capillary to guide the sample across said test field in a flow direction. The test element also includes first and second measurement locations offset from each other in the flow direction. The measurable property is measured in at least one first measurement location, providing at least one first measurement value, and it is measured in at least one second measurement location, providing at least one second measurement value.
    Type: Application
    Filed: September 18, 2015
    Publication date: January 14, 2016
    Applicant: Roche Diabetes Care, Inc.
    Inventors: Joachim Hoenes, Christian Ringemann, Andreas Weller
  • Publication number: 20150286778
    Abstract: Methods are provided for detecting an analyte concentration/presence in a body fluid sample that include providing a set of at least two different evaluation rules, each evaluation rule adapted to derive a set characteristic values from an optical measurement curve, where at least one first characteristic value is derived from at least one first evaluation rule and at least one second characteristic value is derived from at least one second evaluation rule. The methods also include performing at least one multivariate analysis of the at least one first and second characteristic values by using at least one predetermined multivariate evaluation algorithm to derive at least one estimate value for at least one target variable Y of the state variables. The methods also include determining at least one analyte concentration by using the at least one target variable Y. Also provided are computer programs and devices that incorporate the same.
    Type: Application
    Filed: June 19, 2015
    Publication date: October 8, 2015
    Applicant: Roche Diabetes Care, Inc.
    Inventors: Simon Aigner, Gabriele Chemnitius, Carina Horn, Bernd Limburg, Timo Ottenstein, Wolfgang Petrich, Markus Plum, Christian Ringemann, Markus Serr
  • Publication number: 20140242622
    Abstract: An analytical apparatus is disclosed for detecting at least one analyte in a sample, where in an analyte measurement at least an electrical or optical property changeable by presence of the analyte at least one test chemical of a test element is recorded, and where the analytical apparatus also can perform at least one quality measurement on the at least one test chemical such as an intrinsic luminescence, which is recorded and from the intrinsic luminescence a conclusion is drawn on a quality of the test chemical and thus the test element. Methods also are disclosed for detecting at least one analyte in a sample that include a quality measurement of the at least one test chemical of the test strip.
    Type: Application
    Filed: May 14, 2014
    Publication date: August 28, 2014
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Wolfgang Petrich, Carina Horn, Nelli Steinke, Christian Ringemann, Alexa von Ketteler
  • Patent number: 8580579
    Abstract: The invention relates to novel and improved photostable rhodamine dyes of the general structural formulae I or II and their uses as fluorescent markers, e.g. for immunostainings and spectroscopic and microscopic applications, in particular in conventional and stimulated emission depletion (STED) microscopy and fluorescence correlation spectroscopy.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: November 12, 2013
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Stefan Hell, Vladimir N. Belov, Kirill Kolmakov, Volker Westphal, Marcel Lauterbach, Stefan Jakobs, Christian Wurm, Christian Eggeling, Christian Ringemann
  • Publication number: 20120100559
    Abstract: The invention relates to novel and improved photostable rhodamine dyes of the general structural formulae I or II and their uses as fluorescent markers, e.g. for immunostainings and spectroscopic and microscopic applications, in particular in conventional and stimulated emission depletion (STED) microscopy and fluorescence correlation spectroscopy. The partially deuterated analogues are useful as molecular mass distribution tags in mass spectroscopic applications.
    Type: Application
    Filed: April 26, 2010
    Publication date: April 26, 2012
    Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Stefan Hell, Vladimir N. Belov, Kirill Kolmakov, Volker Westphal, Marcel Lauterbach, Stefan Jakobs, Christian Wurm, Christian Eggeling, Christian Ringemann